initi price target
difficult alway motion futur
fruit medic revamp take time pharma recov
decidedli neg rx suppli chain much
howev complet mis-tim upgrad share prior
materi de-rat year ep estim increasingli
confid result improv balanc year
macro headwind drug price abat cite less visibl
desir ep path much uncertainti come
trajectori medic busi undergon massiv
transform current midst integr sizabl deal
remain confid strategi pursu howev cite
time need execut turnaround patient recoveri busi
declin upon time deal
valuat decad low visibl inflect remain mix
furthermor util broadli challeng sign
improv invest also still put segment
order firm ex us sale channel base factor
recent sale china busi see downsid risk
forecast certainli initi first blush contend may take longer
recoveri evid said sentiment appear terribl
share valuat near decad low hefti dividend
yield present support stock current limit downsid risk all-
see mean revers argument prefer see
anoth result would like primari work medic
prior becom construct given dynam see risk
reward balanc thu initi share in-lin rate
thing watch tone gener price medic omx trajectori
debat like strategi shift given management
transit put take impact medic
busi relationship offer stabil growth
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average p/
 basi translat vs average
downsid risk potenti resumpt independ
price war result materi margin degrad signific profit
pressur signific downtick sell-sid gener deflat without
similar movement buy side margin result overal compress
challeng integr patient recoveri asset period
mix overal medic perform sluggish util
upsid risk om firm improv base medic
busi invest period subsid synergi ramp becom
partnership expans enhanc alreadi success exist
relationship recent pass tax reform free capit quickli
de-lever post patient recoveri return capit sharehold
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi pt
difficult alway motion futur
last page report import disclosur regard stock report
tabl content
debat like strategi shift given management transit
debat put take impact medic busi
debat relationship offer stabil growth option
point differenti vs st
iv valuat risk price-to-earnings discount vs visibl
 conclus initi await reacceler
divest distribut busi china
thesi result improv
balanc await proof point
medic strategi prior becom construct
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk challeng integr patient recoveri
period increas competit deflat
retail busi account revenu
new regim follow much legaci game plan
serv current role sinc
retir januari
held number senior oper sale
financ role year cardin
previous gari mari west wireless health
institut jnj comprehens care group
previous serv presid us pharma
distribut evp pharma oper
debat like strategi shift given transit
georg barrett transform cardin
cardin spent bn medic
expans differ medic devic aim
help reduc cost mani high price item
drive total healthcar spend
current ceo georg barrett join cardin
sinc institut broad array strateg
increas dividend yield
enter china plan divest given
address cah rel weak specialti
continu add heft pharma via tuck-in
invest cardin medic busi
cardin invest gener medic
devic addit scale see next box
mike kaufmann like continu vein
div pay-out may peak shift repo/m
georg barrett recent announc retir
effect januari replac mike
georg step chairman nov
jorg gomez current cfo medic becom cfo
mike jorg cardin veteran year
given signific involv realiz
current strategi new team unlik institut
major strateg pivot short-to-medium term
dont expect make dramat chang
weve built mike ep call
gross debt ebitda
new manag unlik herald new era w/ bia dividend vs repurchas key
yearassetproduct areasacq lt cardiolog recoverymdt patient care dvt nutrit bn januari
debat put take impact medic
pois disrupt medic suppli industri
omi/medlin select aggress price
amazon march transform virtual everi
segment economi compani seem
activ eye segment could larg scale
medic suppli distribut next
amazon busi alreadi featur array basic
medic suppli infus pump cathet iv bag
sutur etc price lower competitor
due regulatori hurdl though question
whether could sell higher-end product
implant cardiolog orthoped devic drug
requir licens commod item particularli
non-hospit set would notabl easier
recent acquisit perform mix
cah medic busi face varieti hw
cordiss perform sinc acquisit stellar
earli va announc
synergi taken longer ramp expect
cah lack histor presenc outsid us
build manufactur back offic
howev recent commerci momentum
fx hw last quarter
caus mm hw
patient recoveri newli close perform
expect also benefit cordi invest
select provid medic product reduc
size cah prior contract bn
full effect began impact
inventori step compress initi accret
cardin face suppli challeng glove relat
old manufactur contract result mm
payment regain direct distribut certain market
one time repeat futur
medic remain key swing factor share w/ nt headwind vs lt opportun
debat relationship offer stability/growth option
red oak prove strateg modest ep accret
cvss win optumrx increas scale
found decemb run
follow summer red oak largest us-focus
drug buy entiti bn gener purchas
headquart foxborough jv jointli
staf fund
base size dispar
agre pay mm
rais mm eight year red oak
hit perform target
estim red oak therefor provid steadi
hsd percent ep accret per year provid
major earn tailwind although increment less
given benefit look expans opportun
would red oak expans over-the-counter look like
red oak expans specialti drug
given success red oak gener drug one
potenti sourc increment earn growth could
come expans adjac area over-
over-the-counter product current repres bn
revenu bn
could see sourc save
specialti drug could anoth area save red
given negoti dynam specialti drug
estim save potenti
potenti ep accret specialti drug
potenti ep accret over-the-counter product
model summari point differenti vs street
swing factor pharma omx cadenc medic om growth patient recoveri
point
st given
conserv view
primarili mix drive
st
given
risk await visibl
million except per share data fy end june organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs prior reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
metric increment intrigu given under-perform seek clariti path
risk point balanc risk reward profil execut medic integr crucial given challeng
potenti resumpt independ price war result materi margin degrad signific profit pressur
signific downtick sell-sid gener deflat without similar movement buy side margin result overal compress
challeng integr patient recoveri asset period mix overal medic perform sluggish util
om firm improv base medic busi invest period subsid synergi ramp becom increasingli appar
recent combin creat new vertic partnership expans enhanc alreadi success exist relationship
recent pass tax reform free capit quickli de-lever post patient recoveri return capit sharehold
conclus initi pt upsid
increment clariti path ep prefer prior capit notabl depress valuat
decidedli neg rx suppli chain much howev complet
mis-tim upgrad share prior materi de-rat year ep estim
increasingli confid result improv balanc year
macro headwind drug price abat cite less visibl desir ep path
much uncertainti come trajectori medic busi undergon
massiv transform current midst integr sizeabl deal
remain confid strategi pursu howev cite time need
execut turnaround patient recoveri busi declin upon time deal
furthermor util broadli challeng sign improv
invest also still put segment order firm ex us sale channel
base factor recent sale china busi see downsid risk
forecast certainli initi first blush contend may take longer recoveri evid
said sentiment appear terribl share valuat near decad low
hefti dividend yield present support stock current limit downsid risk
all-in see mean revers argument prefer see anoth result
would like primari work medic prior becom construct
given dynam see risk reward balanc thu initi share rate
thing watch tone gener price medic omx trajectori commentari
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
